Department of diagnostic drugs and phages
PRODUCTION OF IMMUNOBIOLOGICAL DRUGS IN NSCEDI
RSE on REM «M. Aikimbayev’s National Scientific Center for Especially Dangerous Infections» of the Ministry of Healthcare of the Republic of Kazakhstan is the only domestic manufacturer of drugs for the prevention and diagnosis of especially dangerous infections.
Since 1951, the live dry plague vaccine and diagnostic bacteriophages have been produced. In 1967, the production of erythrocyte antigen and immunoglobulin diagnostics was started, and in 1970 – for cholera, tularemia, brucellosis.
Today, about 40 types of drugs are produced for the diagnosis of especially dangerous (plague, cholera, tularemia, anthrax, brucellosis) and other infectious diseases (pseudotuberculosis, yersiniosis, pasteurellosis, leptospirosis, salmonellosis, shigellosis).
The products are represented by the following drugs:
— live dry plague vaccine for humans
— erythrocyte diagnostics, their ingredients
— diagnostic bacteriophages
— hemolized blood
— nutrient medium
— PCR test systems
A comparative study of the sensitivity and specificity of MIBD with similar drugs showed that NSCEDI drugs are not inferior in quality to foreign analogues.
The products are delivered to all regions of the Republic of Kazakhstan, as well as to countries of the near and far abroad. The drugs are exported to neighboring countries – Russia, Kyrgyzstan, Uzbekistan, Turkmenistan, etc., as well as to Mongolia.
The main consumers are anti-plague stations, branches of the RSE on REM «National Center of Expertise», clinical and diagnostic laboratories, veterinary service, other consumers (distributors of the manufacturer’s products, blood centers, etc.).
The use of diagnostic drugs developed and produced in the scientific center allows practical health services to conduct timely examinations of extensive foci of especially dangerous infections, and to conduct timely sanitary and preventive measures to prevent the spread of especially dangerous infectious diseases.
Live dry plague vaccine
From 1 January 2016, the EU member States formed a single common market for medicines that meet the requirements of good pharmaceutical practices (GMP).
NCSEDI has prepared a feasibility study for the creation of a complex for the production of preventive drugs in accordance with GMP requirements. Documents are being prepared for obtaining a positive conclusion in the MNE of the Republic of Kazakhstan.
For 2020-2022, it is planned to build a complex for the production of immunobiological drugs in accordance with GMP requirements.